Effects of i.v. dynorphin A(1–17) and U69,593 on serum prolactin levels (n = 4–5)
| Linear regression | ED501-a (95% CL) | Maximum1-b (95% CL) | Dose Ratio |
|---|---|---|---|
| dyn A(1–17) | 0.0012 (0.00079–0.0018) | n/a | |
| quad/dyn1-c | 0.022 (0.0034–0.14) | n/a | 18 |
| Nonlinear regression | |||
| dyn A(1–17) | 0.0011 (0.00074–0.0016) | 72.1 (60.3–83.9) | |
| U69,593 | 0.0030 (0.0016–0.0057) | 81.2 (59.4–102.9) | |
| quad/U691-c | 0.032 (0.018–0.059) | 82.2 (59.3–105.1) | 10 |
↵1-a ED50 values in (mg/kg); the quadazocine/dynorphin A(1–17) data did not fit a sigmoidal dose-effect curve, and were therefore analyzed by linear regression. The dynorphin ED50 value was also recalculated by linear regression for direct comparison.
↵1-b maximum effect (ng/ml), determined from non-linear regression (sigmoidal dose-effect curve). Mean preinjection baselines for dynorphin A(1–17) and U69,593 were less than 3 ng/ml.
↵1-c quadazocine (0.32 mg/kg s.c.) pretreatment